Status:
COMPLETED
QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia
Lead Sponsor:
Royal Prince Alfred Hospital, Sydney, Australia
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Diabetes Related Complications
Eligibility:
All Genders
Phase:
NA
Brief Summary
Hypoglycaemia is the most common acute complication of diabetes and can limit therapeutic efforts to improve glycaemic control. It is a potential side effect of drugs used to treat diabetes, particula...
Detailed Description
Background/Scientific Basis: Hypoglycaemia is the most common acute complication of diabetes and can limit therapeutic efforts to improve glycaemic control. It is a potential side effect of the drugs...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- A history of symptomatic or documented hypoglycaemia
- Currently treated with a sulphonylurea ± any anti-diabetic agent/s other than insulin
- Currently performing home blood glucose monitoring and willing to do seven tests a day during the study period
Exclusion
- Type 1 diabetes
- Current treatment with insulin
- LBBB and conduction anomalies that preclude QT analysis
- Drugs that prolong QT interval
- Family history of Long QT syndrome
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT02298803
Start Date
January 1 2015
End Date
January 1 2016
Last Update
February 28 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.